Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.42 |
| ▸ | TMPRSS15 | P98073 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631250 | 0.88 | NQO2 (0.44) | NQO2ALDH1A1MAPTKDM4EPRSS1 | |
| SCHEMBL548447 | 0.87 | NQO2 (0.51) | NQO2ALDH1A1MAPTKDM4EPKM | |
| SCHEMBL548327 | 0.86 | NQO2 (0.49) | NQO2ALDH1A1PRSS1TMPRSS15HPGD | |
| SCHEMBL5485793 | 0.86 | NQO2 (0.53) | NQO2ALDH1A1MAPTKDM4EHPGD | |
| SCHEMBL7988304 | 0.78 | SMN1; SMN2 (0.44) | ALDH1A1PRSS1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL548438 | 0.78 | NQO2 (0.50) | NQO2ALDH1A1PRSS1TMPRSS15NR4A2 | |
| SCHEMBL14599566 | 0.74 | NQO2 (1.00) | NQO2ALDH1A1PRSS1HPGDHSD17B10 | |
| SCHEMBL549298 | 0.74 | NQO2 (0.47) | NQO2ALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL549163 | 0.71 | NQO2 (0.40) | NQO2ALDH1A1MAPTKDM4EPRSS1 | |
| SCHEMBL549333 | 0.71 | NQO2 (0.53) | NQO2ALDH1A1MAPTKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1242059-B1 | NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES | UNIV NORTH CAROLINA (US) | 2007-03-21 | — | — | EP | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-6649652-B2 | Hypotensive agents; hyperglycemic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-11-18 | — | — | US | claimed |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-15 | — | — | US | claimed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| US-6503940-B2 | Aids therapy | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-01-07 | — | — | US | disclosed |
| US-6486200-B1 | Prodrugs for antimicrobial amidines | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-11-26 | — | — | US | disclosed |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | NQO2 667/4885ALDH1A1 571/4885MAPT 790/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | NQO2 132/4885ALDH1A1 662/4885MAPT 4349/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | NQO2 129/4885ALDH1A1 1543/4885MAPT 4795/4885 |
| US-20030092755-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | NQO2 396/4885ALDH1A1 976/4885MAPT 4868/4885 |
| US-20020019437-A1 | Novel prodrugs for antimicrobial amidines | NR1H3, APEH, NR1H2 | NQO2 396/4885ALDH1A1 976/4885MAPT 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.